Precision Biosciences (DTIL) Current Leases (2020 - 2026)
Precision Biosciences (DTIL) posted quarterly Current Leases of $1.6 million for Q1 2026, up 14.07% year-over-year from $1.4 million in Q1 2025, and up 3.32% quarter-over-quarter from $1.5 million in Q4 2025.
Precision Biosciences (DTIL) Current Leases (2020 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Current Leases for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 14.07% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 14.07% YoY), while the FY2025 annual figure was $1.5 million, up 14.17% from the prior year.
- Current Leases grew to $1.6 million in Q1 2026 per DTIL's latest filing, from $1.5 million in the prior quarter.
- Across five years, Current Leases topped out at $2.5 million in Q2 2023 and bottomed at $1.1 million in Q4 2023.
- Historically, Current Leases has averaged $1.6 million across 5 years, with a median of $1.5 million in 2023.
- Annual changes were most pronounced in 2023 — Current Leases advanced 29.68% — and 2024, when it sank 51.06%.
- Precision Biosciences' Current Leases stood at $1.7 million in 2022, then slumped by 32.48% to $1.1 million in 2023, then climbed by 16.5% to $1.3 million in 2024, then increased by 14.17% to $1.5 million in 2025, then climbed by 3.32% to $1.6 million in 2026.
- Business Quant data shows DTIL's Current Leases at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Precision Biosciences | 228.28 Mn | 140.73 Mn | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 1.98 Mn |
| Jun 30, 2022 | 1.93 Mn |
| Mar 31, 2022 | 1.87 Mn |
| Dec 31, 2021 | 1.82 Mn |
| Sep 30, 2021 | 2.12 Mn |